Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study
Johan Hansson(Karolinska Institutet), Axel Hauschild(University Hospital Schleswig-Holstein), Natalie Dimier(Roche (United Kingdom)), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Lisa Licitra(University of Milan), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Nicole Basset‐Séguin(Université Paris Cité), Kate Fife(Addenbrooke's Hospital), Jean‐Jacques Grob(Aix-Marseille Université), B. Guillot(Université de Montpellier), Nicolás Meyer(Hôpitaux Universitaires de Strasbourg), D. Scott Ernst, Laurent Mortier, L. Thomas(University of Liverpool), Thomas Karagiannis(Microsoft (United States)), Rainer Kunstfeld(Vienna General Hospital), Reinhard Dummer(University Hospital of Zurich), Yeun Mi Yim(Genesys (United States)), Brigitte Dréno(Nantes Université), Karen Bartley(Genesys (United States)), A. Fittipaldo(Roche (United Kingdom))
Cited by 26
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k